2026-01-15 - Analysis Report
## Thermo Fisher Scientific Inc Financial Report

### Company Overview
Thermo Fisher Scientific Inc, a leader in scientific instruments and life science technology, has been driving innovation in laboratories worldwide.

### Return Rate Comparison
| Ticker | Cumulative Return |
| --- | --- |
| TMO | 42.09% |
| VOO (S&P 500) | 92.89% |
| Divergence | -55.20 |

TMO's cumulative return is lower than the S&P 500's, resulting in a divergence of -55.20.

### Alpha, Beta Analysis
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 21.0% | 17.1% | 17.0% | 1.1 | 84.1B |
| 2017-2019 | 46.0% | 17.1% | 29.0% | 1.1 | 122.1B |
| 2018-2020 | 22.0% | 17.1% | 1.0% | 0.8 | 175.0B |
| 2019-2021 | 77.0% | 15.0% | 34.0% | 0.8 | 250.7B |
| 2020-2022 | 8.0% | 25.4% | 10.0% | 0.8 | 206.9B |
| 2021-2023 | -30.0% | 28.6% | -31.0% | 0.9 | 199.4B |
| 2022-2024 | -37.0% | 24.4% | -57.0% | 0.9 | 195.4B |
| 2023-2025 | -17.0% | 27.2% | -79.0% | 0.8 | 217.7B |

The data shows fluctuations and changes in the company's growth and performance across different years.

### Stock Price Fluctuation Analysis
| Figure | Value |
| --- | --- |
| Close | $621.83 |
| Last-market | $621.83 |
| 5-day SMA | $613.94 |
| 20-day SMA | $591.89 |
| 60-day SMA | $579.53 |

The prices show the fluctuation of the stock over the past few days. The 5-day, 20-day, and 60-day moving averages indicate the short-term and long-term trends in stock prices.

### RSI, PPO Index Indicators & Delta
| Indicator | Value |
| --- | --- |
| RSI | 69.62 |
| PPO | 0.41 |
| Market Risk Indicator (MRI) | 0.7 |
| Hybrid Signal | Buy |
| Recent relative divergence change | -2.80 (-) |
| 7-day Rank change | 0 (0) |
| 7-day Dynamic Expected Return change | 0.00 (0) |
| Expected Return | -54.10% |

The RSI and PPO index indicators suggest the stock is overbought. The market risk indicator and hybrid signal also suggest a buy but with a caution due to the stock's expected return.

### Recent News & Significant Events
Please refer to the provided headlines/links:

* [2026-01-14] Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now? - TradingView
* [2025-12-31] Here’s What Lifted Thermo Fisher Scientific (TMO) in Q3 - Yahoo Finance
* [2026-01-14] Will Thermo Fisher’s AI Push and Leadership Shuffle Redefine TMO’s Innovation and Execution Narrative? - simplywall.st
* [2026-01-12] Thermo Fisher (TMO) stock slips after COO exit disclosed; AI lab deals put focus on JPM talk - TechStock²
* [2026-01-12] How Thermo Fisher and NVIDIA want to turn routine labs into AI powerhouses - Stock Titan
* [2026-01-13] Lobbying Update: $30,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver Quantitative

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 651.52 / 750.00 / 575.00

The consensus opinion among analysts suggests buying the stock, with an average target price of $651.52.

### Earnings Analysis
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

The earnings per share (EPS) and revenue show a positive trend, indicating strong financial performance.

### Revenue and Profitability Analysis
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

The revenue and profit margin indicate a stable and healthy financial performance.

### Capital and Profitability Analysis
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

The equity and return on equity (ROE) indicate a stable and healthy financial performance.

### Comprehensive Analysis
The comprehensive analysis of Thermo Fisher Scientific Inc's financial performance shows:

* A lower cumulative return compared to the S&P 500
* Fluctuating growth and performance across different years
* Short-term and long-term trends in stock prices
* Indications of overbuying based on RSI and PPO index indicators
* Positive EPS and revenue trends
* Stable and healthy financial performance in terms of revenue, profit margin, equity, and ROE
* Analyst consensus opinion suggesting buying the stock

Please note that this analysis is based on the provided data and should not be considered as investment advice.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.